HHHenry Hirschberg

Henry Hirschberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Henry Hirschberg has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sonodynamic therapy inhibition of invasive glioma cells from tumor spheroids

    by Akhil Chandekar, Sophia Renee Laurel, Keya Gupta, Tyler Lee, Nicole Wakida, Henry Hirschberg


  • Open Access

    Enhancing the Efficacy of Radiation Therapy by Photochemical Internalization of Fibrin-Hydrogel-Delivered Bleomycin

    by Sophia Renee Laurel, Keya Gupta, Jane Nguyen, Akhil Chandekar, Justin Le, Kristian Berg, Henry Hirschberg

    Background/Objectives: Although the use of radiation-sensitizing agents has been shown to enhance the effect of radiation on tumor cells, the blood–brain barrier (BBB) impedes these agents from reaching brain tumor sites when provided systemically. Localized methods of sensitizer delivery, utilizing hydrogels, have the potential to bypass the blood–brain barrier. This study examined the ability of photochemical internalization (PCI) of hydrogel-released bleomycin to enhance the growth-inhibiting effects of radiation on multi-cell glioma spheroids in vitro. Methods: Loaded fibrin hydrogel layers were created by combining thrombin, fibrinogen, and bleomycin (BLM). Supernatants from these layers were collected, combined with photosensitizer, and added to F98 glioma spheroid cultures. Following light (PCI) and radiation treatment, at increasing dosages, spheroid growth was monitored for 14 days. Results: PCI of released BLM significantly reduced the radiation dose required to achieve equivalent efficacy compared to radiation or BLM + RT alone. Both immediate and delayed RT delivery post-BLM-PCI resulted in similar degrees of growth inhibition. Conclusions: Non-degraded BLM was released from the fibrin hydrogel. PCI of BLM synergistically increased the growth-inhibiting effects of radiation treatment compared to radiation and BLM, as well as radiation acting as a single treatment.

  • Open Access

    Enhancing the Efficacy of Radiation Therapy by Photochemical Internalization of Fibrin Hydrogel Delivered Bleomycin

    by Sophia Laurel, Keya Gupta, Jane Nguyen, Akhil Chandekar, Justin Le, Kristian Berg, Henry Hirschberg

    Background/Objectives: Although the use of radiation-sensitizing agents has been shown to enhance the effect of radiation on tumor cells, the blood-brain barrier (BBB) impedes these agents from reaching brain tumor sites when given systemically. Localized methods of sensitizer delivery, utilizing hydrogels, have the potential to bypass the blood-brain barrier. This study examined the ability of photochemical internalization (PCI) of hydrogel-released bleomycin to enhance the growth-inhibiting effects of radiation on multi-cell glioma spheroids in vitro; Methods: Loaded fibrin hydrogel layers were created by combining thrombin, fibrinogen, and bleomycin (BLM). Supernatants from these layers were collected, combined with photosensitizer, and added to F98 glioma spheroid cultures. Following light (PCI) and radiation treatment, at increasing dosages, spheroid growth was monitored for 14 days; Results: PCI of released BLM significantly reduced the radiation dose required to achieve equivalent efficacy compared to radiation or BLM+RT alone. Both immediate and delayed RT delivery post BLM-PCI resulted in similar degrees of growth inhibition; Conclusion: Non-degraded BLM was released from the fibrin hydrogel. PCI of BLM synergistically increased the growth-inhibiting effects of radiation treatment compared to radiation and BLM, and radiation acting as a single treatment.

  • Open Access

    Light-Activated Local Drug Delivery From Hydrogels: Potential for GBM Treatment

    by Lina Nguyen, Gabrielle Romena, Ethan Nguyen, Cassandra Tran, Kaitlyn Nguyen, Ananya Devarajan, Henry Hirschberg

    Following post-operative treatment, the vast majority of GBMs recur, usually within 2 cm of the tumor resection margin. Since these tumors seldom metastasize outside the CNS, improved localized therapies should prove beneficial. Drug delivery systems (DDS) that allow control over drug release by an externally applied energy, such as light, have the potential of improving the results of chemotherapy. Light-activated hydrogel DDS, implanted in the operative cavity formed by tumor resection, bypasses the blood brain barrier and allows for a precise spatio-temporal control of drug release or drug activation. Localized, on-demand release of anticancer drugs to normal brain infiltrated by tumor cells should therefore improve therapeutic efficacy and minimize systemic, drug-related side effects. Various forms of light-activated hydrogels have utilized near infrared, visible or ultraviolet wavelength irradiation. One form of hydrogel, fibrin glue (FG), composed of a combination of fibrinogen and thrombin, has several characteristics that make it well-suited for this form of sustained release drug delivery. Unlike most synthetic hydrogels, FG is a natural product and has been used clinically in surgery for decades, so its biocompatibility and lack of toxicity has been clearly proven. The light-driven drug activation technology, photochemical internalization (PCI) has been shown to enhance the intracellular efficacy of chemotherapeutic agents released from fibrin glue. A summary of the light-activated hydrogel techniques developed for the site and temporal-specific delivery of chemotherapy for the treatment of GBM will be discussed in this review.


  • Open Access

    Photochemical Internalization for Intracellular Drug Delivery. From Basic Mechanisms to Clinical Research

    by Waseem Jerjes, Theodossis A. Theodossiou, Henry Hirschberg, Anders Høgset, Anette Weyergang, Pål Kristian Selbo, Zaid Hamdoon, Colin Hopper, Kristian Berg

    Photochemical internalisation (PCI) is a unique intervention which involves the release of endocytosed macromolecules into the cytoplasmic matrix. PCI is based on the use of photosensitizers placed in endocytic vesicles that, following light activation, lead to rupture of the endocytic vesicles and the release of the macromolecules into the cytoplasmic matrix. This technology has been shown to improve the biological activity of a number of macromolecules that do not readily penetrate the plasma membrane, including type I ribosome-inactivating proteins (RIPs), gene-encoding plasmids, adenovirus and oligonucleotides and certain chemotherapeutics, such as bleomycin. This new intervention has also been found appealing for intracellular delivery of drugs incorporated into nanocarriers and for cancer vaccination. PCI is currently being evaluated in clinical trials. Data from the first-in-human phase I clinical trial as well as an update on the development of the PCI technology towards clinical practice is presented here.